Health Care Delivery

Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.

Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.

In a pair of lively debates at the International Stroke Conference 2026, experts from around the world discussed controversies in stroke care.

City St. George’s researchers identified 9 genetic signatures and epigenetic changes driving lapatinib resistance in HER2-positive breast cancer.

Oral Wegovy shifts GLP-1 obesity costs: insurance may match injectables, while cash-pay and pharmacy platforms unlock lower prices and aid programs.

Clearer definitions, tailored programs and policies, and telestroke care could help close rural stroke care disparities.

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, discusses the growing role of real-world treatment data in CLL and other cancers.

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations.

Prior authorization remains a major health care barrier, causing delays and frustrations for insured adults seeking necessary treatments.

Addressing poor medication adherence should be a top priority in health plans to ensure short- and long-term benefits in health outcomes and financial stability.

Explore critical health equity issues as barriers to care access and health disparities that impact treatment for allergic rhinitis and childhood vaccinations.

This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.

The upcoming price negotiations are the third cycle since the Inflation Reduction Act was passed in 2022.

AAP’s 2026 immunization schedule continues protection against 18 diseases as the CDC reduces its recommendations to 11.

Experts raise concerns that CDC childhood immunization changes could reduce vaccine uptake and weaken trust in public health guidance.

Minnesota physicians warn ICE activity in hospitals and clinics is deterring care, undermining patient safety, and worsening health outcomes.

With the CDC’s decision to roll back recommendations to vaccinate for several conditions, questions have arisen as to what that may mean in the US.

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

Ongoing phase 3 trials target improved therapies for hematologic malignancies, focusing on CLL, multiple myeloma, and pediatric leukemia outcomes.

Patients with allergic rhinitis face prolonged symptoms and inadequate treatment, highlighting a need for better awareness and access to allergen immunotherapy.

Research reveals that socioeconomic status significantly impacts survival rates in young adults with metastatic colorectal cancer, emphasizing the need for health equity initiatives.